drugset / Trial / NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Timeline
- Start
- 2025-06-01
- Primary completion
- 2028-05-01
- Completion
- 2028-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | FWD1802 | Unknown | — | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |